The subfornical organ (SFO) is an important sensory circumventricular organ implicated in the regulation of fluid homeostasis and energy balance. We investigated whether the SFO is activated by the hormone cholecystokinin (CCK). CCK1 and CCK2 receptors were identified in the SFO by RT-PCR. Dissociated SFO neurons that responded to CCK (40/77), were mostly depolarized (9.2 Ϯ 0.9 mV, 30/77), but some were hyperpolarized (Ϫ7.3 Ϯ 1.1 mV, 10/77). We next examined the responses of SFO neurons in vivo to CCK (16 g/kg ip), in the presence and absence of CCK1 or CCK2 receptor antagonists (devazepide; 600 g/kg and L-365,260; 100 g/kg, respectively), using the functional activation markers c-Fos and phosphorylated extracellular signal-related kinase (p-ERK). The nucleus of the solitary tract (NTS) served as a control for CCK-induced activity. There was a significant increase in c-Fos expression in the NTS (259.2 Ϯ 20.8 neurons) compared with vehicle (47.5 Ϯ 2.5). Similarly, in the SFO, c-Fos was expressed in 40.5 Ϯ 10.6 neurons in CCK-treated compared with 6.6 Ϯ 2.7 in vehicle-treated rats (P Ͻ 0.01). Devazepide significantly reduced the effects of CCK in the NTS but not in SFO. L-365,260 blocked the effects of CCK in both brain regions. CCK increased the number of p-ERK neurons in NTS (27.0 Ϯ 4.0) as well as SFO (18.0 Ϯ 4.0), compared with vehicle (8.0 Ϯ 2.6 and 4.3 Ϯ 0.6, respectively; P Ͻ 0.05). Both devazepide and L-365,260 reduced CCK-induced p-ERK in NTS, but only L-365,260 reduced it in the SFO. In conclusion, the SFO represents a novel brain region at which circulating CCK may act via CCK2 receptors to influence central autonomic control.
SENSORY CIRCUMVENTRICULAR ORGANS (CVOs) are small brain regions that lack a complete blood-brain barrier. They are characterized by the presence of fenestrated blood capillaries and are highly vascularized (16) . These characteristics permit the CVOs to have direct contact with circulating factors and hormones (25, 75) . CVOs have been found to have essential roles in the control of metabolic and endocrine functions. The subfornical organ (SFO) is an important sensory CVO involved in the regulation of fluid homeostasis and drinking behavior (31, 68) . It is endowed with a number of functional receptors for signals important in the regulation of these behaviors, such as angiotensin (46) and atrial natriuretic peptide (69) . Following activation, neurons of the SFO exert their effects by direct and indirect efferent projections to important hypothalamic nuclei-controlling autonomic functions such as the paraventricular nucleus, the supraoptic nucleus, the median preoptic nucleus, lateral hypothalamus, and the arcuate nucleus (73) .
The SFO has also been found to be a site for the actions of hormones that are implicated in the control of food intake and energy balance. For example, studies have shown that the peptide mediators amylin (64) and ghrelin (58) influence the activity of SFO neurons. Further support for the role of the SFO in the actions of energy balance hormones came from the discovery that leptin, an adiposity factor known to be involved in energy homeostasis, activated SFO neurons. Specifically, leptin was found to cause electrophysiological actions in isolated SFO neurons and in vivo to increase phosphorylated STAT3 immunoreactivity in neurons of the SFO (71) . Direct administration of leptin into the SFO has been shown to modulate cardiovascular function in anesthetized animals (72, 86) , but whether the SFO mediates part of the inhibitory actions of leptin on food intake has yet to be examined.
Measurement of mRNA expression levels for a number of receptors present in the SFO has demonstrated the expression of receptors involved in the regulation of numerous autonomic functions (73) . While many of these have now been investigated and found to be functionally expressed on SFO neurons (12, 17, 21, 50, 71, 78) , the presence of cholecystokinin (CCK) receptors has not been examined further.
CCK is a hormone secreted from intestinal I cells and has a role in the regulation of food intake and was the first anorexigenic peptide to be described (26) . It is secreted in response to feeding and is an important signal for meal termination (48, 49) . Vagal primary afferents are known as the main site of action of CCK for the reduction of food intake, leading to the activation of the area postrema and the nucleus of the solitary tract in the brain stem (7, 63) . CCK acts on two distinct receptors, CCK 1 and CCK 2 , both of which belong to the seven transmembrane G protein-coupled receptors family. CCK 1 is primarily distributed peripherally, although it is localized in some regions in the brain, whereas CCK 2 is found mostly in the central nervous system (CNS) (82) . A number of signaling pathways are activated in response to the stimulation of both CCK receptors. The Gq member of the G protein receptor family is coupled to both CCK 1 and CCK 2 receptors (61) . The principal target of activation of Gq-coupled receptors is phospholipase C, which results in the formation of inositol trisphosphate leading to the release of calcium from intracellular stores. In addition to activation of phospholipase C, phospholipase A2 and phospholipase D (PLD) are activated by CCK receptors. Activated PLD leads to the formation of diacylglycerol and activation of protein kinase C (PKC). PKC subsequently activates the mitogen-activated protein kinase (MAPK) pathways with subsequent activation of the ERK1/2 pathway (15).
This study was performed to validate the mRNA microarray data suggesting the expression of CCK receptors in SFO and examine potential roles for CCK in controlling the activity of SFO neurons. We show that the SFO expresses CCK receptors and that CCK receptor stimulation leads to activation of SFO neurons in vitro and in vivo.
METHODS

Animals and drugs.
All the experimental procedures were carried out in accordance with the guidelines of the Canadian Council on Animal Care after approval from the Health Sciences Animal Care Committee of the University of Calgary, or Queen's University. Male Sprague-Dawley rats between 200 and 300 g (in vivo studies) or 100 and 150 g (in vitro studies) were purchased from Charles River (Montreal, Quebec, Canada). Upon arrival, they were housed under specific pathogen-free conditions on a reversed 12-h light-dark cycle with free access to food and water for 1 wk before the experiment. Cholecystokinin (sulfated CCK-8; catalog no. 069-03) was purchased from Phoenix (Phoenix Pharmaceuticals, Burlingame, CA). Devazepide and L-365,260 were purchased from Tocris (Tocris Bioscience, Minneapolis, MN).
Reverse-transcription PCR. SFO tissue was acutely dissected out of rat brain and total RNA was extracted using RNAqueous kit (Ambion) according to the manufacturer's directions. The total RNA from two SFOs was then DNase treated by adding a mixture of 1 l 10ϫ buffer with MgCl 2, 7 l diethylpyrocarbonate (DEPC)-treated H2O, and 1 l deoxyribonuclease to the total RNA and incubating the solution at 37°C for 30 min. After incubation, 1 l of 25 mM of EDTA was added to the solution and incubated at 65°C for 10 min. Oligo-dT based cDNA was synthesized using Superscript III reverse transcriptase kit (Invitrogen, Carlsbad, CA) to make a final reaction volume of 20 l. The QIAGEN Multiplex kit (QIAGEN, Mississauga, ON, Canada) was used for PCR reactions to amplify cDNA. Ten microliters of the SFO cDNA was added to a PCR reaction containing 50 l 2ϫ QIAGEN Multiplex PCR Master Mix, 10ϫ primer mix, 0.2 M of each primer, 10 l 5ϫ Q-Solution, and DEPC-treated H 2O to a final volume of 100 l. The reaction tube was first denatured at 95°C for 15 min and then cycled 30 times through a protocol of 94°C for 30 s, 60°C for 90 s, 72°C for 90 s, and finally 72°C for 10 min. Primer sets previously described were used to identify CCK receptors (CCK 1 and CCK2, Table 1 ) mRNA. PCR products were run and visualized on electrophoresis gel containing 2% agarose and ethidium bromide. The surplus products from the PCR reaction were sequenced by Robarts Institute (London, ON, Canada) to confirm identity.
Subfornical organ neuron dissociation. Male Sprague-Dawley rats (100 -150 g) maintained on a 12-12 h light/dark cycle and allowed ad libitum access to food and water were used for all experiments. SFO neurons were dissociated using protocols adapted from those described previously (1, 22) . Briefly, animals were decapitated, and the brain was removed immediately and placed in oxygenated, ice-cold solution containing (in mM): 87 NaCl, 2.5 KCl, 25 NaHCO 3, 0.5 CaCl2, 7 MgCl2, 1.25 NaH2PO4, 25 glucose, and 75 sucrose. A block of tissue containing the hippocampal commissure was dissected from the whole brain and the SFO, which can be readily distinguished from all adjacent tissue, was isolated and removed. SFO was then placed in hibernate media (Brain Bits, Springfield, IL) with 2 mg/ml papain (Worthington, Lakewood, NJ) and incubated in a water bath at 30°C for 30 min. SFO tissue was washed using hibernate media with 1ϫ B27 supplement (Invitrogen, Burlington, ON, Canada), triturated, centrifuged at 200 rpm for 4 min, and resuspended in neurobasal-A/ B27 (Invitrogen). Dissociated neurons were plated on glass-bottom dishes (MatTek Ashland, MA) and incubated at 37°C in 5% CO 2. Electrophysiological experiments were normally performed within 1-4 days of dissociation, during which time period membrane properties (resting membrane potential, input resistance, and spike amplitude) remained stable, and contacts between neurons were not observed.
Electrophysiology. Current clamp recordings were obtained from SFO neurons using a Multiclamp 700B patch-clamp amplifier (Molecular Devices, Sunnyvale, CA). Analogue signals recording membrane potential and whole cell currents were digitized at 5 kHz and filtered at 1 kHz using a Cambridge Electronics Design Micro1401 interface and Spike2 (version 6) data acquisition software. Patchclamp recording in the whole cell mode was performed using the perforated patch method with nystatin (0.2 mg/ml) as the poreforming antibiotic as previously described (57 Dissociated SFO neurons were perfused with external recording solution (32°C) at a rate of 1.6 ml/min. Once whole cell configuration was achieved, cells were defined as neurons by the presence of voltage-gated Na ϩ currents under voltage-clamp configuration and the occurrence of spontaneous or current-evoked action potentials (amplitude greater than 50 mV) in current clamp configuration. A calculated junction potential of Ϫ14.4 mV was added to the membrane potential of recorded neurons. After a minimum 200 s of stable baseline membrane potential recording, 100 pM or 10 nM of CCK (Phoenix Pharmaceuticals) was applied followed by a wash with external recording solution. Responsiveness of SFO neurons was determined by comparing membrane potential of neurons before and after CCK application. Membrane potential changes were determined by comparing the average membrane potential during the 100-s control period, with sequential 100-s periods during and following CCK application. SFO neurons were considered responsive to CCK if the difference in membrane potential was greater than twice the standard deviation of the control baseline value and was followed by a return toward baseline values following return to aCSF. Reported changes in membrane potential represent the 100-s mean with the largest change from the control period.
Determination of plasma CCK concentrations. Rats that were fasted overnight were divided into two groups (n ϭ 4 each). Blood was withdrawn from the tail into EDTA-coated tubes from each animal at time 0. At the beginning of the dark cycle, one group received an intraperitoneal injection of CCK-8 (16 g/kg) and the other group was provided with a liquid Ensure meal (15 ml, which is fully consumed in 20 min). Blood was withdrawn at 30 and 60 min after injection or after the start of feeding. Collected blood was centrifuged at 3,000 rpm for 15 min at 4°C. The plasma samples were stored for a limited time at Ϫ80°C before plasma CCK was measured using an ELISA kit that measures COOH-terminal CCK immunoreactivity (catalog number EK-069-04, Phoenix, Belmont, CA) follow- ing the manufacturer's instructions. This assay has been previously used by others to assess total circulating CCK levels in a variety of conditions (29, 36, 53, 80) . The minimum detectable concentration by this assay is 0.06 ng/ml, and the linear range is from 0.06 to 0.85 ng/ml. At 30 min, CCK levels were 0.30 Ϯ 0.11 ng/ml after CCK injection compared with 0.23 Ϯ 0.02 ng/ml after Ensure (n ϭ 4/group). Similarly, at 60 min, CCK levels were 0.42 Ϯ 0.10 ng/ml after CCK injection compared with 0.36 Ϯ 0.02 ng/ml after Ensure (n ϭ 4/group). It is important to note that these levels reflect total circulating COOH-terminal CCK immunoreactivity and are not specific to sulfated CCK-8. The circulating values of CCK-8 determined by other specific techniques have been previously reported to be in the range of 4 -17 pM (4.6 -19.4 pg/ml) (5, 44, 59, 60) .
Immunohistochemistry. Rats adapted to daily handling and injection with saline for at least 5 days were fasted overnight. On the day of the experiment, rats were treated with CCK-8 (16 g/kg ip) with or without CCK receptor antagonists or their respective vehicles 1 h before the dark cycle. CCK antagonists were injected 30 min before the injection of CCK. Ninety minutes after CCK injection, animals were anesthetized with pentobarbital sodium (50 mg/kg), perfused intracardially with 200 ml saline, followed by 300 ml 4% paraformaldehyde in phosphate-buffered saline (PBS, pH 7.3). Brains were carefully removed and fixed in 4% paraformaldehyde at 4°C overnight and then cryoprotected with 20% sucrose in PBS at 4°C overnight. Specimens were embedded in OCT compound (Tissue-Tek, Sakura Finetek Japan, Tokyo, Japan) and were sectioned in the coronal plane on a cryostat (35 m). Floating sections were collected with reference to the rat brain atlas (Paxinos and Watson) (56) containing the subfornical organ (SFO, bregma Ϫ0.58 mm), nucleus of the solitary tract (NTS, bregma Ϫ14.04 mm), and area postrema (AP, bregma Ϫ14.04 mm).
Floating sections were washed three times in 10-min intervals in PBS containing 0.1% Triton X-100 and then incubated in blocking buffer composed of PBS containing 10% normal donkey serum for 1 h at room temperature. Sections were incubated in primary antibody rabbit anti c-Fos (1:2,000; Oncogene Science, Cambridge, MA) at 4°C for 48 h. Tissues were then washed in PBS containing 0.1% Triton X-100 three times for 10 min and incubated in donkey antirabbit CY3 (1:100; no. 711-166-152, Jackson ImmunoResearch Laboratories, West Grove, PA) at room temperature for 2 h. Sections were mounted and examined using a Zeiss Axioplan fluorescence microscope (Carl Zeiss, Jena, Germany). The gray-scale images were captured by digital camera (Qimaging, Surrey, BC, Canada). Numbers of c-Fos-positive neurons in SFO, AP, and NTS were counted using a computer-based image analysis system (ImagePro plus software) by setting both an intensity value and a size by an observer unaware of treatment conditions. The mean number of c-Fos-immunoreactive cells from three sections per animal was compared among different animal groups, and images for the same region were obtained under the same exposure.
Immunoreactivity for phosphorylated extracellular signal-related kinase (p-ERK) was assessed using the above procedure modified to collect tissues 15 min after CCK-8 (16 g/kg) administration and with the primary AB being rabbit anti-pERK (1:500; Santa Cruz, Carlsbad, CA).
Statistics. All statistical analyses were performed using GraphPad Prism (version 5.0; San Diego, CA). When two groups were compared, data were analyzed using Student's t-test. Analysis of variance (ANOVA) test was used for multiple comparisons followed by Bonferroni-corrected post hoc tests.
RESULTS
Cholecystokinin (CCK) receptors 1 and 2 are expressed in the SFO.
While recent microarray studies have suggested the presence of CCK 1 and CCK 2 receptor expression in the SFO (73), such observations have yet to be validated using RT-PCR. We therefore performed RT-PCR on cDNA prepared from mRNA harvested from SFO tissue to confirm whether these receptors were in fact expressed in the SFO. The total cDNA underwent PCR amplification using primer sets designed specifically to amplify CCK 1 and CCK 2 cDNA. As illustrated in the gel shown in Fig. 1 , the RT-PCR reaction amplified both CCK 1 and CCK 2 indicating that both receptors are expressed in the SFO.
CCK-8 influences the activity of SFO neurons. We therefore examined the effects of activation of CCK receptors on the excitability of SFO neurons. Whole cell current-clamp recordings were obtained from 77 dissociated SFO neurons, and their responsiveness was then characterized based on changes in membrane potential in response to bath administration of CCK. All cells included in our analysis showed action potentials Ͼ50 mV in amplitude, and the mean resting membrane potential of these SFO neurons was Ϫ59.0 Ϯ 0.9 mV. A minimum 100-s stable baseline period of recording was obtained from all neurons tested before bath application of 10 nM or 100 pM CCK, and membrane potential was then monitored for a minimum of 200 s after return to aCSF perfusion. In all neurons at least a partial recovery of membrane potential to baseline values was observed, although complete recovery could take more than 45 min and therefore was sometimes not observed in cells where recordings were not maintained for this extended period of time. We observed changes in mean membrane potential at intervals of 100 s after CCK application to determine the effects of CCK on membrane potential and the peak 100 s mean change in membrane potential from baseline values. Of the SFO neurons that were tested with 10 nM CCK, we observed two distinct responsive groups that either depolarized (39% of cells; 30/77, mean membrane potential change 9.2 Ϯ 0.9 mV), or hyperpolarized (13% of cells; 10/77, mean membrane potential change Ϫ7.3 Ϯ 1.1 mV) in response to CCK application, as illustrated in Fig. 2 , A and B and summarized in Fig. 2C . The remaining cells tested (48%, 37/77) were unaffected by CCK (membrane potential change of less than 2 times SD obtained in 100-s baseline recording, mean membrane potential change Ϫ0.5 Ϯ 0.3 mV). Similarly, SFO neurons tested with 100 pM CCK, either depolarized (35% of 
Effect of CCK-8 on c-Fos immunoreactivity in SFO.
After confirmation of the expression of CCK 1 and CCK 2 in SFO tissue and the observed responsiveness of SFO cells to CCK, we wanted to test if these receptors respond to a systemic injection of a hypophagic dose of CCK-8. We used neuronal c-Fos expression as a marker of neuronal activity in response to intraperitoneal injection of CCK-8. The NTS and the AP were used as positive control regions for CCK-induced neuronal activation. As shown in Fig. 3, A and B, CCK-8 (16 g/kg) induced a robust expression of c-Fos in the AP and NTS (Bregma Ϫ13.68 to Ϫ14.8) compared with the vehicle-treated group. In the NTS, the highest increase in c-Fos immunoreactivity was observed at the level of AP (which is shown in Fig.  3B ; Bregma Ϫ13.68 to Ϫ14.8) followed by the rostral NTS (Bregma Ϫ13.3 to Ϫ13.24). The caudal NTS (Bregma Ϫ14.6 to Ϫ14.3) showed the lowest increase in c-Fos expression compared with vehicle-treated animals (data not shown). In the SFO (Bregma Ϫ0.8 to Ϫ1.4), CCK-8 caused a significant increase in c-Fos immunoreactivity (18.6 Ϯ 2.6) compared with the vehicle-treated group (0.3 Ϯ 0.3) as illustrated in Fig.  3 , C and D. According to the rostrocaudal organization, the SFO is classified into three regions: rostral, central, and caudal. The central region is the richest in neuronal cell bodies and glial cells; however, rostral and caudal regions consist mainly of nerve fibers with a small number of cell bodies and glial cells. The core region of the SFO is more vascularized with abundant fenestrated capillaries, making this region potentially more accessible to circulating agents. Interestingly, we observed that the increase in c-Fos expression was more prominent in the core of the central region of the SFO (Bregma Ϫ0.92 to Ϫ1.3, Fig. 3D ).
Effect (Fig. 4, B and C) . However, the pattern of SFO c-Fos expression in devazepide-treated animals was quite different from that of CCK-treated animals. Devazepide treatment was associated with a diffuse, widespread c-Fos expression, whereas c-Fos expression in response to CCK alone was confined to the central core of the SFO.
L-365,260 (100 g/kg) significantly reduced the CCK-induced increase in the number of c-Fos immunoreactive neurons in the AP (CCK; 52.5 Ϯ 2.5 vs. L-365,260/CCK; 15.5 Ϯ 2.5,) and the NTS (CCK; 166.5 Ϯ 12.5 vs. L-365,260/CCK; 116.0 Ϯ 9.0, Fig. 5A ). In the SFO (Fig. 5, B and C) , L-365,260 also attenuated CCK-induced c-Fos immunoreactivity (L-365,260/CCK; 2.5 Ϯ 1.5 vs. CCK; 18.0 Ϯ 3.0).
When we combined both CCK 1 and CCK 2 receptor antagonists with CCK-8 treatment, c-Fos expression in the AP and the NTS was attenuated to the levels of the vehicle-treated group (Fig. 6A) . Interestingly, in the SFO, combining the two antagonists failed to block the CCK-induced c-Fos expression (Fig. 6B) , and also, when given without CCK resulted in a significant increase in c-Fos immunoreactivity in the SFO (vehicle/vehicle; 2.3 Ϯ 0.6 vs. devazepideϩL-365,260; 11.25 Ϯ 2.2, Fig. 6B) .
Effect of CCK-8 on the level of p-ERK in the SFO.
Previous reports have shown that the inhibitory effect of CCK on food intake is mediated through the activation of the ERK1/2 pathway in the brain stem (mainly the NTS), so we investigated whether activation of SFO neurons by CCK is mediated through the same pathway. We measured p-ERK immunoreactivity in response to CCK-8 alone or in combination with devazepide or L-365,260. We used the NTS as a positive control region and as shown in Fig. 7 , A and C, CCK induced a significant increase in p-ERK immunoreactivity in the NTS (vehicle/vehicle; 12.3 Ϯ 2.9 vs. vehicle/CCK; 37.4 Ϯ 6.3) as well the SFO (vehicle/vehicle; 11.3 Ϯ 2.9 vs. vehicle/CCK; 28.7 Ϯ 3.6; Fig. 7B ). The pattern of p-ERK activation, which was distributed peripherally in the SFO (mainly in neurons, as well as some nerve fibers), was different from that observed with c-Fos, which was localized to the central core of the SFO as shown in Fig. 7C . In the NTS, this effect was attenuated by combination of CCK with devazepide or L-365,260. In the SFO, devazepide did not alter the effects of CCK on p-ERK immunoreactivity while L-365,260 reduced the responses to CCK. Consistent with the c-Fos data, devazepide alone induced a significant increase in p-ERK immunoreactivity in the SFO.
DISCUSSION
The present study provides evidence that the SFO is a potential CNS site at which circulating CCK may exert its actions. Our RT-PCR data demonstrate, for the first time, the presence of both CCK 1 and CCK 2 receptor mRNA in the SFO, whereas electrophysiological studies indicate that about 50% of SFO neurons respond to CCK, with the majority showing rapid reversible depolarization. The activation of c-Fos expression in the SFO in response to a systemic administration of CCK (16 g/kg ip) demonstrates the ability of SFO neurons to respond to circulating CCK, which does not readily cross the blood-brain barrier (54) . Moreover, the increase in p-ERK immunoreactivity in response to CCK represents further evidence of CCK actions in the SFO which use similar signaling pathways to that reported in the NTS (3). Thus this study suggests that the SFO may act as a novel site of action for circulating CCK.
There are numerous studies using both receptor autoradiography and in situ hybridization that have examined the distribution of CCK receptors in the brain and have not reported the presence of CCK receptors in the SFO. This is probably due to their low level of expression in this brain region. A gene chip analysis revealed low levels of CCK receptor expression in the SFO (73) . Thus in the present study we extended this work by performing RT-PCR for both CCK receptors in the SFO and confirmed the expression of CCK receptors in this region. To assess if these receptors were functional, we examined whether isolated SFO neurons had the capacity to respond to CCK. Not unlike many brain-gut peptides, CCK both depolarized and hyperpolarized different subpopulations of SFO neurons with about 50% of neurons responding and the majority of responding neurons showing depolarization. The concentrations of CCK used in these studies falls in the range of concentrations used previously by us in studying CCK actions on the area postrema (1, 10, and 100 nM) (77) or by others studying CCK effects on vagal afferent neurons (20 nM) (88) and on the NTS (100 nM) (4). Leptin, an adipocyte-derived hormone implicated in the control of energy balance, has also been shown to affect SFO neuronal activity, with ϳ64% of the neurons tested responsive (71) . The magnitude of membrane potential change in neurons that depolarized in response to leptin was 7.2 Ϯ 0.6 mV(9.2 Ϯ 0.9 mV in case of CCK). On the other hand, the mean membrane potential change in neurons that responded with hyperpolarization was Ϫ6.9 Ϯ 0.8 mV (Ϫ7.3 Ϯ 1.1 mV in case of CCK). CCK and leptin are not the only metabolic hormones acting in the SFO. Another example of a metabolic hormone that affects the excitability of SFO neurons is insulin. Lakhi et al. (39) recently reported that insulin influences 70% of SFO neurons tested, with 33% of neurons hyperpolarizing and 37% depolarizing. Ghrelin, an orexigenic hormone secreted from the stomach, has also been shown to affect SFO neurons (58) . Ghrelin induced depolarization of about 30% of the neurons tested (39% in case of CCK). In the same study, amylin, an anorexigenic hormone secreted from the pancreas, was shown to activate 60% of SFO neurons but interestingly, single neurons responded to either ghrelin or amylin, but never to both peptides (58) . It should be noted that the SFO also responds to a wide variety of other circulating factors that directly or indirectly affect feeding and metabolism, such as angiotensin II (41), neurokinin B (55), and vasopressin (2) . Taken together, these data suggest that the SFO is poised to sense a variety of circulating signals and thus likely represents an important central site of integration of peripheral circulating factors.
Having shown that SFO neurons express CCK receptors and respond to CCK in vitro, we then examined activation in vivo using c-Fos immunoreactivity as a marker of neuronal activity. c-Fos is an immediate early gene that is expressed by activated neurons (14) . Although c-Fos measurement is a well-established semiquantitative method of measuring neuronal activation, its use has a number of limitations, thus when using c-Fos as a marker, one should consider a number of points. First, there is a critical time in which c-Fos is maximally expressed in response to a stimulus. In our experiments, animals were studied 90 min after CCK administration, since maximal c-Fos expression in response to a stimulus (32), or specifically CCK, has been shown to be between 90 and 120 min (37, 52, 89) . Second, exposure to stress induces c-Fos expression, so it is important to adapt the animals to handling and manipulation to decrease the levels of basal c-Fos expression. The low level of c-Fos expression in all vehicle-treated animals is indicative that our animals underwent careful conditioning and were not stressed at the time of the study.
To examine the neuronal activation in response to CCK we used a relatively high dose (16 g/kg), that nevertheless gave circulating plasma levels of a similar magnitude to that of an Ensure test meal measured using a commercial ELISA kit for total COOH-terminal CCK immunoreactivity. This dose is above the level selective for satiety (26, 47) but similar to that used by others who have examined the expression of c-Fos in the brain (65) and below doses found to produce taste aversion (51) . It is important to note that several CCK forms have been detected in the plasma, for example, CCK-8, CCK-22, and CCK-58 (23, 33, 60) . However, with the use of techniques that minimize CCK peptide degradation, CCK-58 is the only circulating form of CCK in the rat (19, 76) . CCK-58 produces a prolonged inhibition of food intake compared with CCK-8, inhibiting food intake for as long as 60 min, and a longer latency to first meal and intermeal interval (27, 28) . However, CCK-58 is not commercially available, which explains the more common use of the octapeptide form in most research. Further work on the actions of the physiological forms of CCK on the SFO is required.
One consideration with an effect where food intake is reduced is whether the effects observed are because of malaise. This has previously been examined. Ervin et al. (18) showed that the aversive effect of CCK is related to the route of administration and is different in rats compared with humans. The lowest dose they used was 24 g/kg, which did not produce taste aversion when administered intraperitoneally, suggesting the animals were not suffering malaise. In addition, McCutcheon et al. (45) measured aversion by studying pica behavior (ability to cause kaolin eating); a measure of gastric distress and concluded that a dose of 20 g/kg of CCK did not produce pica. Since the doses of CCK we used are below these levels, we think it is unlikely that the activation of neurons in the SFO by CCK is because of malaise.
Using the AP and the NTS as a positive control for CCK-8 induced c-Fos activation, we have shown for the first time the induction of c-Fos in the SFO in response to intraperitoneal administration of CCK-8. The distribution of c-Fos immunoreactivity in the brain stem was entirely consistent with previous reports (8, 24, 81) . c-Fos expression in the SFO was confined to the central core of the SFO, a region that anatomical and tracing studies have demonstrated to characterized by an abundance of fenestrated capillaries as well as cell bodies of output neurons (13) . This pattern of distribution of c-Fos immunoreactive neurons is highly suggestive of a direct effect of circulating CCK on SFO neurons with likely projections to hypothalamic autonomic control nuclei.
We also undertook studies to identify the CCK receptor subtype mediating this response, by examining the effect of devazepide (CCK 1 receptor antagonist) and L-365,260 (CCK 2 receptor antagonist) on CCK induced c-Fos expression in the SFO, as well as in the brain stem. As previously reported (8, 30) , devazepide blocked CCK-induced c-Fos in the AP and NTS; however, it did not affect SFO c-Fos expression. These findings suggest that CCK-induced c-Fos in the SFO is not mediated by the CCK 1 receptor. On the other hand, blockade of CCK 2 receptor by L-365,260 resulted in attenuation of the number of c-Fos immunoreactive neurons in the SFO, as well as in the brain stem, supporting a role for the CCK 2 receptor in mediating depolarization in these regions. Interestingly, rats treated with devazepide alone had increased c-Fos immunoreactivity in the SFO but not in the brain stem; a possible explanation of this effect is that CCK 1 receptor stimulation might be activating neurons that send inhibitory signals to other neuronal population, thus blocking CCK 1 using devaz- epide is releasing this inhibitory input leading to activation of these neurons, leading to the expression of c-Fos. The pattern of devazepide-induced c-Fos expression combined with the fact that devazepide crosses the blood-brain barrier (85) raises the possibility that devazepide-induced c-Fos might be through acting on other brain regions and not by a direct effect on the SFO. As noted above, a possible explanation of this effect is that CCK 1 receptor stimulation might be activating neurons that send inhibitory signals to other neuronal populations. A situation like this has been shown in the amygdala, where Chung and Moore (10), using whole cell-patch recordings, found that CCK-8 activates GABAergic interneurons thus increasing inhibitory transmission; however, in their study, this effect was CCK 2 receptor mediated. The induction of c-Fos by devazepide has been previously shown by Li and Rowland (40) in the supraoptic nucleus, dorsomedial hypothalamus, and the medial magnocellular subdivision of the hypothalamic paraventricular nucleus. Pretreatment with a combination of CCK 1 and CCK 2 antagonists resulted in a similar increase in c-Fos immunoreactivity in the devazepide-treated group. This finding rules out the possibility that blocking CCK 1 receptor alone might have caused basal circulating CCK to act on CCK 2 receptors, hence activating the neurons.
To confirm and extend these findings, we also examined neuronal activation using the MAP kinase system. Activation of the MAP kinase signaling cascade has been demonstrated to be associated with activation of the two subtypes of CCK receptors (11) , and this pathway can be activated upstream of c-Fos expression or through a completely different signaling cascade from the one leading to c-Fos induction (84) . Previous data has shown that systemic administration of CCK leads to increased levels of phosphorylated form of ERKs, pERK1/2, in the NTS (3, 6) . Thus, by immunohistochemical localization of pERK, we studied the effect of systemic CCK on the number of pERK immunoreactive cells in the SFO. CCK-8 caused an increase in pERK immunoreactive neurons in the SFO and in the NTS, a region previously shown to display an increase in pERK immunoreactivity in response to CCK (3, 6) . The activation of the ERK pathway has been shown to be essential for the inhibitory action of CCK on food intake, since the use of an infusion of a MEK inhibitor into the fourth ventricle inhibited ERK cascade with subsequent attenuation of CCK food-suppressing effect (79) . The pattern of CCK-induced pERK in the SFO was different from c-Fos expression pattern, suggesting a different mechanism of activation. The CCKinduced p-ERK-positive SFO cells were more confined to the periphery of the SFO, which raises the possibility that CCK elicits differential effects in different population of SFO neurons. Our results show that CCK-induced c-Fos and p-ERK in the SFO is mediated through the CCK 2 receptor. The importance of CCK 2 receptor in CCK-mediated functions has been previously reported by a number of studies performed mostly in mice. For example, CCK 2 receptor-deficient mice showed elevated body temperature, increased body weight, and water consumption, suggesting a role for CCK 2 receptor in the processes regulating energy homeostasis (83). Chen et al. (9) also found increased body weight but reduced fat mass in mice lacking the CCK 2 receptor. The previous data provide evidence that the SFO represents another CNS target for the actions of circulating CCK. We do not have evidence defining the role of the SFO in mediating CCK function, however, given the fact that CCK exerts a variety of physiological functions, a number of possibilities exist. These include potential CCK actions in the SFO to modulate cardiovascular function that occur in parallel to the meal termination process (42) . CCK causes splanchnic vasodilatation that is followed by depressor and bradycardic effects (70) . It also inhibits renal sympathetic vasomotor nerve activity (38) , resulting in increased blood flow to the gut and kidney to enhance the process of digestion and to deal with the additional fluid load following a meal. The SFO may also represent an additional site in the CNS involved in the cardiovascular effects of CCK, a suggestion supported by the established roles of SFO in cardiovascular regulation (20, 34) . In addition, as mentioned earlier, lack of CCK 2 receptors resulted in increased water consumption in mice (83) , raising the possibility that the SFO may act as a player mediating such effects on drinking behavior. Finally, although the well-accepted roles of CCK to inhibit food intake and terminate meals are believed to be mainly mediated through the vagus nerve (24, 47, 81) , there are studies suggesting the presence of an extra vagal site for CCK action. For example, chemical ablation of the afferent vagal nerves using the neurotoxin capsaicin either, into the fourth ventricle (to desensitize central vagal afferents) (66, 74) or intraperitoneal (to affect peripheral vagal afferents) (43, 74) attenuated, but did not abolish, the effect of CCK on food intake. In addition, surgical ablation of the vagus by subdiaphragmatic vagotomy has been shown to reduce but not abolish the effect of CCK on food intake (35, 63) . On the other hand, Reidelberger (62) showed that blockade of CCK 1 receptors with devazepide induced an increase in food intake in vagotomized rats, suggesting that CCK inhibits food intake by mechanisms independent of an intact vagus. In a similar experiment, after capsaicin was utilized to desensitize vagal afferents in rats, devazepide maintained its food intake-increasing effect (67) . It should be noted that in both studies, devazepide, which crosses the blood-brain barrier, was used, which might explain its effect on food intake on other brain regions. More recently, Zhang and Ritter (87) reported that reduction of food intake by CCK was abolished in vagotomized and capsaicin-treated rats only if CCK is given intraperitoneally, whereas the effect of intravenous CCK was only partially attenuated in these rats, raising the possibility that circulating CCK may access extravagal sites of action such as the SFO and AP.
Perspectives and Significance
In conclusion, we show that the SFO expresses CCK receptors and that CCK receptor activation leads to activation of SFO neurons in vitro and in vivo. These results add further to understanding of the role of the SFO in metabolic regulatory control. It remains to be determined whether the inhibitory effects of CCK on meal termination are in part mediated by the SFO or whether the SFO plays other roles. It is intriguing that CCK 2 receptors seem to be the dominant excitatory receptor in the SFO compared with CCK 1 in the brain stem.
